Wechat

Website

Chinese Journal of Oncology Prevention and Treatment ›› 2024, Vol. 16 ›› Issue (5): 615-621.doi: 10.3969/j.issn.1674-5671.2024.05.16

Previous Articles     Next Articles

Summary of evidence for the management of drug-related symptoms during endocrine therapy in breast cancer patients

  

  • Online:2024-10-25 Published:2024-11-06
  • Supported by:

Abstract: Objective To search, evaluate and integrate the best evidence for the management of drug⁃related symptoms during endocrine therapy in breast cancer patients, so as to provide reference for clinical practice. Methods According to the "6S" model of evidence⁃based resources, computer⁃aided literature search was conducted on BMJ Best Practice, Up To Date, Website of World Health Organization (WHO), Guidelines International Network (GIN), PubMed, CNKI, and Wanfang Database. The types of literature covered guidelines, systematic review/Meta⁃analysis, evidence summary, clinical decision⁃making, and expert consensus. The search period was from the establishment of the database to April 2023. Two evidence⁃based professionals evaluated the quality of the included literatures and extracted the data. Results A total of 16 references were included, including 3 clinical decision⁃makings, 2 guidelines, 1 expert consensus, and 10 systematic reviews. A total of 27 pieces of the best evidence of drug⁃related symptom management in endocrine therapy for breast cancer patients were summarized with respect to 6 aspects, including risk assessment, individualized management, general symptom management strategy, drug intervention, non⁃drug intervention, and cognitive behavioral intervention. Conclusions The 27 pieces of summarized evidence can be used for the symptom management of drug⁃related side effects in endocrine therapy in breast cancer patients, and specific evidence should be selected according to cultural background, clinical situation, patient's symptoms and willingness.

Key words: Breast cancer, Endocrine therapy, Symptom management, Summary of evidence

CLC Number: 

  • R737.9